Apixaban for the prevention of venous thromboembolism in people ...

Has the source for all costs been described? Y
Have discount rates been described and justified
given the target decision-maker?
Are the utilities incorporated into the model
appropriate?
Is the source for the utility weights referenced? Y
Are the methods of derivation for the utility
weights justified?
Have all data incorporated into the model been
described and referenced in sufficient detail?
Has the use of mutually inconsistent data been
justified (i.e. are assumptions and choices
appropriate)?
Y
Y/N
Y/N
Is the process of data incorporation transparent? Y/N
If data have been incorporated as distributions,
has the choice of distribution for each parameter
been described and justified?
If data have been incorporated as distributions, is
it clear that second order uncertainty is reflected?
Have the four principal types of uncertainty been
addressed?
If not, has the omission of particular forms of
uncertainty been justified?
Have methodological uncertainties been
addressed by running alternative versions of the
model with different methodological
assumptions?
Is there evidence that structural uncertainties
have been addressed via sensitivity analysis?
Has heterogeneity been dealt with by running the
model separately for different subgroups?
Are the methods of assessment of parameter
uncertainty appropriate?
If data are incorporated as point estimates, are
the ranges used for sensitivity analysis stated
clearly and justified?
Is there evidence that the mathematical logic of
the model has been tested thoroughly before
use?
Y
Y
Y
Y
Y
N.A.
Y
Y
Y
Y/N
Y
Y
91
Copyright 2011 Queen’s Printer and Controller of HMSO. All rights reserved.
Utilities incorporated in the model are based on a
wide variety of methods.
Due to lack of data some utility inputs were not
reference case (for instance no preference data
from the public). This was further justified in the
clarification phase.
Inclusion of trials in the indirect comparison and
MTC for efficacy not safety was not clear.
However, this was resolved in the clarification
phase.
It was stated that only parameters not included in
the deterministic sensitivity analyses were
included in the PSA. Although some parameters
were included in both, this indicates that not all
parameter uncertainty was reflected in the PSA.
…